Vanda Pharmaceuticals | VNDA - Bénéfice Avant Impôts





Bénéfice Avant Impôts Changement Date
Acadia Pharmaceuticals USD 3.98M 22.34M 2026-03
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
Akebia Therapeutics USD -11.24M 12.39M 2025-12
Alnylam Pharmaceuticals USD 221.65M 60.52M 2026-03
Anika Therapeutics USD 764K 3M 2025-12
Arrowhead Research USD 28.27M 7.85M 2025-12
AstraZeneca USD 3.91B 1.28B 2026-03
Bristol-Myers Squibb USD 1.47B 1.64B 2025-12
Eli Lilly USD 8.27B 1.03B 2025-12
Enanta Pharmaceuticals USD -22.71M 95.08M 2024-12
Esperion Therapeutics USD 63.67M 95M 2025-12
Halozyme Therapeutics USD 180.33M 281.18M 2026-03
Heron Therapeutics USD -2.95M 14.54M 2025-12
Insmed USD -162.1M 164.84M 2026-03
J&J USD 7.82B 2.86B 2026-03
Lexicon Pharmaceuticals USD -12.77M 16.02M 2025-09
Ligand Pharmaceuticals USD 56.78M 84.36M 2025-12
Merck USD 3.42B 3.32B 2025-12
Minerva Neurosciences USD 22.51M 30.74M 2024-09
Moderna USD -799M 612M 2025-12
Novartis USD 5.17B 637M 2025-09
Pfizer USD 5.18B 6.82B 2026-03
PTC Therapeutics USD -2.46M 136.62M 2026-03
Puma Biotechnology USD 20.61M 24.76M 2024-09
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Sanofi EUR -1.16B 5.5B 2025-12
Takeda JPY -52.48B 186.34B 2026-03
Teva Pharmaceutical Industries USD 753M 662M 2026-03
Ultragenyx Pharmaceutical USD -184M 56M 2026-03
Vanda Pharmaceuticals USD -22.92M 16.68M 2024-12
Veracyte USD 29.97M 10.66M 2026-03